Literature DB >> 2983109

Protein stabilization explains the gag requirement for transformation of lymphoid cells by Abelson murine leukemia virus.

R Prywes, J Hoag, N Rosenberg, D Baltimore.   

Abstract

The single protein encoded by Abelson murine leukemia virus is a fusion of sequence from the retroviral gag genes with the v-abl sequence. Deletion of most of the gag region from the transforming protein results in a virus capable of transforming fibroblasts but no longer capable of transforming lymphoid cells. Smaller deletions in gag reveal that p15 gag sequences are responsible for this effect, whereas deletion of p12 sequences had no effect on lymphoid transformation. In transformed fibroblasts, p15-deleted and normal proteins had similar activities and subcellular localization. When the p15-deleted genome was introduced into previously transformed lymphoid lines, its protein product exhibited a marked instability. The tyrosine-specific autophosphorylation activity per cell was less than 1/20th that of the nondeleted protein. Although pulse-Ia-beling showed that the p15-deleted protein was synthesized efficiently, immunoblotting demonstrated that its steady-state level was less than 1/10th that of the nondeleted Abelson protein. The specific instability of the p15-deleted protein in lymphoid cells explains the requirement of these sequences for lymphoid but not fibroblast transformation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983109      PMCID: PMC254769     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  In vitro transformation of lymphoid cells by Abelson murine leukemia virus.

Authors:  N Rosenberg; D Baltimore; C D Scher
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells.

Authors:  O N Witte; N Rosenberg; M Paskind; A Shields; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

4.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

5.  A new method for sequencing DNA.

Authors:  A M Maxam; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

6.  Lymphosarcoma: virus-induced thymic-independent disease in mice.

Authors:  H T Abelson; L S Rabstein
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

7.  The mouse c-abl locus: molecular cloning and characterization.

Authors:  J Y Wang; F Ledley; S Goff; R Lee; Y Groner; D Baltimore
Journal:  Cell       Date:  1984-02       Impact factor: 41.582

8.  Membrane properties of the gag gene-coded p15 protein of mouse type-C RNA tumor viruses.

Authors:  M Barbacid; S A Aaronson
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

9.  Analysis of single- and double-stranded nucleic acids on polyacrylamide and agarose gels by using glyoxal and acridine orange.

Authors:  G K McMaster; G G Carmichael
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

10.  A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus.

Authors:  N Rosenberg; D Baltimore
Journal:  J Exp Med       Date:  1976-06-01       Impact factor: 14.307

View more
  23 in total

1.  Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.

Authors:  R W Rees-Jones; S P Goff
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation.

Authors:  B J Mayer; H Hanafusa
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

3.  Definition of functional domains in P135gag-myb-ets and p48v-myb proteins required to maintain the response of neuroretina cells to basic fibroblast growth factor.

Authors:  C Garrido; D Leprince; J S Lipsick; D Stehelin; D Gospodarowicz; S Saule
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.

Authors:  Chae-Ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

5.  Carboxyl-terminal determinants of Abelson protein important for lymphoma induction.

Authors:  K Parmar; R C Huebner; N Rosenberg
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

6.  Differential requirements of gag and gamma-actin domains for transforming potential of Gardner-Rasheed feline sarcoma virus.

Authors:  J Miyoshi; Y Miyoshi; H Sasai; N Sakai; T Katsumata; T Kakunaga
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

7.  Genetic dissection of functional domains within the avian erythroblastosis virus v-erbA oncogene.

Authors:  M L Privalsky; P Boucher; A Koning; C Judelson
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

8.  Activation of oncogenicity of the c-rel proto-oncogene.

Authors:  B S Sylla; H M Temin
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

9.  Mapping by in vitro constructs of the P100gag-mil region, accounting for induction of chicken neuroretina cell proliferation.

Authors:  J Coll; C Dozier; S Saule; C Henry; B Quatannens; B Debuire; D Stehelin
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

10.  Characterization of the transforming domain of a feline sarcoma virus encoding a fgr-related tyrosine kinase.

Authors:  G Weyrauch; A Barnekow
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.